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Background: TransAtlantic Inter-Society Consensus (TASC) guideline recommended
femoro-popliteal (FP) bypass as standard treatment for TASC C-D lesions. Although
several studies have identified 5-year primary patency for FP bypass of around 70%,
complication rate is high compared with endovascular therapy (EVT). Accordingly,
EVT with nitinol stent implantation has been widely used for FP lesion. However,
long-term results of stenting, especially for TASC C-D lesions, remain unclear. Thus,
this study examined long-term outcomes of nitinol stent implantation for TASC C-D
FP lesions, factors associated with the restenosis and risk stratification according to
predictors.
Methods: Between December 2003 and December 2009, 381 patients with 471 TASC
C-D FP lesions (mean age 72.4 years; 67.5% male) underwent nitinol stent
implantation. Restenosis was defined either by duplex ultrasound or angiography.
Patency was analyzed by Kaplan-Meier estimation. Predictors for restenosis were
determined by Cox multivariate regression analysis, and primary patency rates were
compared between low or high risk groups that were created based on number of
predictors present.
Results: Mean lesion length was 230±65mm. At 6 years, the primary and secondary
patency rate and amputation-free survival rate was 51%, 77% and 72.7%, respectively.
By Cox multivariate regression analysis, female gender (hazard ratio [HR] 1.51; 95%
confidence interval [CI] 1.09-2.10; P=0.014), diabetes (HR 1.73; 95% CI 1.15-2.59;
P<0.01), claudicator (HR 1.73; 95% CI 1.15-2.59; P<0.01), without SMART stent
implantaion (HR 1.66; 95% CI 1.17-2.35; P<0.01), and reference vessel diameter <
6mm (HR 1.49; 95% CI 1.07-2.99; P=0.017) were the predictors for restenosis. Primary
patency in the low-risk group (number of risk factors 0-2) and high-risk group (3-5) at
6 years was 60.0% vs. 35.4%, p<0.0001, respectively.
Conclusion: EVT using nitinol stents yielded acceptable outcomes out to 6 years in
TASC C-D FP lesions. Revascularization strategy for TASC C-D lesions should be
chosen according to risk stratification.
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COMPLIANCE 360°: A Prospective, Randomized, Multicenter Trial
Comparing Balloon Angioplasty to Diamondback 360° Orbital Atherectomy
System in Calcified Femoropopliteal Disease
Raymond Dattilo
St. Francis Health Center, Topeka, KS
Background: Stent placement in the distal superficial femoral and popliteal arteries
is associated with increased risk of stent fracture and restenosis. Lesion calcification
is predictive of vessel dissection and recoil after PTA. This study examines whether
the Diamondback 360° Orbital Atherectomy System (DB360) (Cardiovascular
Systems, Inc., St. Paul, MN), by changing the compliance of calcified femoropopliteal
(FP) lesions through the mechanism of differential sanding, diminishes the frequency
of adjunctive (bailout) stenting without sacrificing intermediate term patency.
Methods: 50 symptomatic patients (66 lesions) from 10 sites with calcified FP lesions
of ≥70% were equally randomized to PTA alone vs. DB360 followed by low pressure
PTA up to 4 atmospheres (atm) with the endpoint of residual stenosis ≤30%. Lesions
failing to achieve this endpoint with the prescribed therapy were then treated with
bailout stenting. Freedom from target lesion revascularization (TLR), including the
need for bailout stenting, or restenosis defined as a peak systolic velocity ratio of ≥2.5
on duplex study at 6 months, was the primary endpoint.
Results: 92.1% of 38 lesions in the DB360 arm and 21.4% of 28 lesions in the PTA
arm (p<0.0001) met the angiographic endpoint after primary therapy. 2 of 25 pts in the
DB360 arm vs. 21 of 25 pts in the PTA arm required bailout stenting (p<0.0001). Mean
maximum balloon pressure (a measure of lesion compliance) in the DB360 arm was
3.9 atm vs. 8.5 atm in the PTA arm (p<0.0001). At 6 months, 4 pts in the DB360 arm
vs. 3 pts in the PTA arm had restenosis (p=NS); 2 of 3 in the PTA arm were in-stent.
Freedom from TLR or restenosis at 6 months was 72.7% (16 of 22 pts) in the DB360
arm and 8.3% (2 of 24 pts) in the PTA arm (p<0.0001).
Conclusion: Compared to PTA alone, orbital atherectomy with low pressure PTA leads
to better luminal gain by improving lesion compliance with less need for adjunctive
stenting when treating calcified FP lesions. Patency at 6 months is comparable to PTA
with a provisional stent strategy.
TCT-94
Results of the ALSTER hypertension registry: first experience with renal
denervation
Martin W Bergmann, Astrid Kleinbongardt, Alessandro Cuneo, Jasper Wedel, Karl
Heinz Kuck
Dep. of Cardiology, St. Georg Hospital, Hamburg, Germany
Background: Renal denervation was found to be effective in drug-resistant
hypertension. Here we dscribe the results of the first 31 patients treated outside the
study criteria regarding reduction of drug intake and effectiveness.
Methods: Between Mai 2010 and January 2011 31 patients were treated with the
Ardian simplicity system. These patients were followed for 6 months with repetitive
diabetes and hypertension monitoring. No side-effects related to the ablation were
documented. Patients were required to have at least 3 medications on board to be
eligible; systolic blood press was measured at least once > 160 mmHg. In addition,
echo criteria regarding diastolic dysfunction, HbA1c as a measure of glycemia control
as well as renal function were closely monitored.
Results: After a 6 months follow up, 65% of patients responded to the therapy with
either a measurable drop in blood pressure measured at the oupatient follow up visit 3
months after the procedure (35%) and/or less dyspnoe on exertion. 16% of patients
reduced their medication in part due to dizziness with the newly decreased blood
pressure. No effect on HbA1c was detected in this cohort; HbA1 was > 5.9% in 55%
of patients. No measurable effect on diastolic dysfunction was found during the above
mentioned follow up period of 6 months.
Conclusion: Renal denervation was found safe and partially effectived; we have since
altered our system. Re-evaluating the patients who did not respond to treatment suggest
duration of hypertensive treatment to be an independent predictor.
TCT-95
Acute And Long-term Follow-up Results Of Renal Angioplasty In Takayasu
Arteritis
Amar Narayan Patnaik, D. S Rao, B. Srinivas
Cardiology, Nizam’s institute of medical sciences, Hyderabad, India
Background: Takayasu arteritis frequently presents with hypertension in young adults.
Stenosis of one or both renal arteries is present in most of them and angioplasty of
these lesions is expected to control hypertension and control renal damage. We present
the acute and long term results of renal angioplasty done for the last 8 years in our
hospital.
Methods: All cases of Takayasu arteritis, diagnosed basing on criteria suggested by
Ishikawa, who underwent percutaneous transluminal renal angioplasty (PTRA) in our
hospital from 2003 were followed up clinically and by a renal Doppler in all cases at
all visits. A cine renal- angiogram was advised at 6 months and 18 month visit. During
2003 to 2008, we performed renal angioplasty in 85 lesions (76 patients; 54 females;
age range 24 to 47 years; mean 29.5±5.65 years). Unilateral lesions were seen in 67
patients and rest had one lesion in each kidney. Ostial lesions constituted % (29/85) of
the cases. Of them 64 cases who had at least 18 months follow-up data were included
for analysis.
Results: Results: Technical success rate for the first PTRA was 90.5% )( 77/85) lesions.
Of the 8 failure cases one with bilateral lesions was sent for emergency surgery due to
renal artery rupture following PTRA and 5 underwent surgical revascularization. Of
the ostial lesions technical success rate was 68.9 % (21/29). There was no mortality in
any case. On a mean follow up of 22.5±8.55 months 19 of 64 cases {23 of 66 lesions
(34.8%)} developed restenosis and 17 of them were successfully redilated. There was
death of one patient with bilateral lesions due to CRF. Cure of hypertension (BP
<140/90 mmHg without need for medication) and improvement (BP<140/90 mmHg
with same or reduced number of medications) was achieved in 25/64(39%) and
24/64(37.5%) respectively. Of the 25 cases with raised serum creatinine 17/25 (68%)
had shown a fall in their values in follow-up (mean 1.91± 1.05mg to 1.3±0.76 mg; p-
<0.005)
Conclusion: PTRA is technically feasible with acceptable acute results. Ostial lesions
are more difficult to be dilated. The restenosis is seen in about one-third of the cases
after successful procedure which can be redilated. Control of hypertension and renal
dysfunction is achieved in a significant number of cases.
TCT-96
Impact of Preexisting Cerebral Ischemia Detected by Magnetic Resonance
Imaging and Angiography on Clinical Outcomes After Coronary Artery Bypass
Graft in Patients Without History of Stroke
Won-Jang Kim, Sun-Joo Jang, Yong Kyu Park, Gyung-Min Park, Yong-Giun Kim,
Jung-Min Ahn, Jong-Young Lee, Duk-Woo Park, Soo-Jin Kang, Seung-Whan Lee,
Young-Hak Kim, Cheol Whan Lee, Seong-Wook Park, Seung-Jung Park
Asan Medical Center, Seoul, Republic of Korea
Background: Limited data existed for long-term clinical outcomes of asymptomatic
brain ischemia after coronary artery bypass grafting (CABG). We sought to assess the
impact of preexisting ischemia detected by brain magnetic resonance imaging and
angiography (MRA) on clinical outcomes after CABG.
Methods: Between Jan. 2003 and May 2009, 3,071 patients underwent CABG in Asan
Medical Center. Preoperative brain MRA was performed in 2,417 patients. Patients
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with history of stroke were excluded and total 2,119 patients were analyzed. Ischemia
was detected by brain MRA in 253 patients (group A), but not in 1866 patients (group
B). Preoperative characteristics, follow-up survival, and cardiac and neurological
events were investigated.
Results: The median follow-up period was 2.2 years. Univariate analysis showed that
patients in group A (65.4 ± 8.3 years) were older than those in group B (63.0 ± 9.0
years) (p<0.001). Diabetes mellitus was more common in group A (48.6%) than group
B (40.9%) (p=0.019). The prevalence of chronic kidney disease was higher in group
A (63 patients: 24.9%) compared with group B (324 patients: 17.4%) (p=0.004). The
prevalence of peripheral vascular disease was higher in group A (13 patients: 5.1%)
than in group B (39 patients: 2.1%) (p = 0.003). Euroscore was higher in group A (4.3
±2.3) than group B (3.6 ±2.2) (p<0.001). Survival rate was significantly lower (93.4%
vs. 90.1%, p = 0.008), and freedom from stroke or major adverse cardiac and
cerebrovascular event were significantly lower in group A (98.0% vs. 96.0%, p = 0.015,
and 91.9% vs. 88.2%, p = 0.001).
Conclusion: Preexisting ischemic findings on brain MRA in patients who undergoing
CABG were related to death, stroke, and major adverse cardiac and cerebrovascular
event.
TCT-97
From US Pivotal Study to 1200 Patients on 6 Continents: A Global Perspective
on the Endurant Stent Graft
Brijeshwar Maini
PinnacleHealth Cardiovascular Institute, Wormleysburg, PA
Background: Endovascular abdominal aortic aneurysm (AAA) has evolved since first
being approved in the US in 1999. Outcomes have changed with increased operator
experience and the approval of new devices. The Endurant stent graft system
(Medtronic, Santa Rosa CA) which was approved in late 2010 is the first next
generation device to be commercialized in the US. This device seeks to expand the
indications of EVAR in short, angulated necks, as well as, patients with small peripheral
access vessels. However, are US pivotal study results indicative of global experience?
Methods: Over 1400 patients have been enrolled in Endurant clinical studies or
registries since first in human studies commenced in Europe. The three studies used in
this analysis are the Endurant European study which enrolled 80 patients, the US
Pivotal study which enrolled 150 patients, and the ENGAGE global registry. Data from
the ENGAGE registry includes results from the first 839 patients at 30 days and the
first 152 patients at 1 year.
Results: Deployment success was achieved in 99.6% of patients across all studies. In
the US Pivotal study there was 0% all-cause mortality at 30 days. In comparison, 30
day all-cause mortality in the EU study and ENGAGE were 2.5% and 0.9%
respectively. At 1 year, there were no incidences of Type I/III endoleak, migration, or
conversion in either the US Pivotal or the EU study. Similarly, there was a 1% incidence
of Type I/III endoleak, no incidence of migration, and a 0.8% incidence of conversion
at 1 year in ENGAGE.
Conclusion: Early and midterm outcomes with the Endurant stent graft system in the
treatment of AAA are consistent across global studies with high clinical success and
low complication rates.
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Carotid Artery Revascularization with Distal Protection in High Surgical Risk
Patients in Routine Clinical Practice: Results of the CABANA Safety
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Background: The multicenter, nonrandomized CABANA Study evaluated
periprocedural outcomes in high surgical risk patients with carotid artery stenosis
treated with the Carotid WALLSTENT plus FilterWire EZ Embolic Protection System
(Boston Scientific Corporation, Natick, MA).
Methods: The study enrolled 32.7% symptomatic and 67.3% asymptomatic patients
at high risk for carotid endarterectomy (CEA) due to prespecified anatomical criteria
and/or medical comorbidities. Study centers were grouped into 1 of 3 tiers based on
having high, medium, or low previous carotid artery stenting (CAS) experience while
individual operators were grouped by their CAS credential-based study training
requirements. Follow-up at 30 days included clinical evaluation and independent
neurologic and NIH stroke scale assessments. The primary endpoint was the 30-day
composite of major adverse events (MAE), including stroke, death, and myocardial
infarction (MI).
Results: Of the 1,097 enrolled patients, technical success was achieved in 1,010
(97.1%); the stroke rate (3.3% [34/1,025]) was a major contributing factor in the overall
rate of MAEs (4.6% [47/1,025]). Most strokes were ipsilateral (88.2%) and ischemic
(85.3%). The overall mortality was 1.3% (13/1,025); the MI rate was 0.5% (5/1,025).
There was no statistically significant association between MAE rates among the 3
center experience tiers (p=0.61) nor among the 3 operator training categories (p=0.26).
However, there was a weak trend towards lower MAE rates at centers with greater
experience and with operators with more CAS training.
Conclusion: Results demonstrate that CAS with Carotid WALLSTENT and FilterWire
EZ is a safe alternative to CEA in high surgical risk patients in routine clinical practice.
The study yielded a low composite rate of 30-day MAEs and low individual rates of
periprocedural stroke, death, and MI. These rates were consistent across centers with
varying levels of CAS experience and operators with varying levels of training on CAS
and the Carotid WALLSTENT/FilterWire EZ System.
TCT-99
The SAPPHIRE Worldwide Carotid Artery Stenting with Embolic Protection
Study: Outcomes to 1-Year with Over 7,600 Patients
Christopher Metzger1, Robert Hibbard2, Douglas Massop3, Richard Smalling4,
Donald Heck5, Maurice Solis6
1Holston Valley Medical Center, Kingsport, TN; 2Bryan Heart Institute, Lincoln, NE;
3Iowa Clinic, Des Moines, IA; 4University of Texas Medical School, Houston, TX;
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Background: Carotid artery stenting (CAS) has become a viable alternative to carotid
endarterectomy, especially in patients considered high risk for surgery due to medical
co-morbidities and anatomically challenging lesions. SAPPHIRE Worldwide is the
largest study to date to evaluate long-term outcomes of CAS in patients at high-risk
for surgery.
Methods: SAPPHIRE Worldwide is a multicenter, prospective, observational study
of CAS performed at multiple centers by physicians with varied experience and
utilizing a formal training program. The primary endpoint of major adverse events
(MAE) included death, myocardial infarction (MI) and all stroke at 30 days, and
ipsilateral stroke was assessed from 31 to 360 days.
Results: To date, over 10,000 patients have been enrolled at 325 participating centers
and completed 30-day follow-up. More than 7,600 patients have completed 1-year
follow-up evaluation. Thirty percent of patients enrolled were symptomatic, and 46%
were over the age of 75 years. At 30-day follow up, the rate of MAE was 4.5% (death
1.3%, MI 0.6%, all stroke 3.3%). Between 30 days and 1 year, 21 additional patients
suffered an ipsilateral stroke for a 1-year MAE rate of 6.1%. MAE was significantly
lower in patients with asymptomatic vs. symptomatic stenosis (5.1% vs. 8.6%,
p<0.0001), and in patients with anatomic high risk factors compared with physiologic
factors (4.2% vs.6.9%, p<0.0001). Age < 75 years was also associated with a lower
risk of adverse events than seen with older patients (4.5% vs. 8.1%, p<0.0001).
Conclusion: Long-term outcomes with this large cohort of patients undergoing CAS,
shows favorable results. The risk of ipsilateral stroke after the periprocedural period
was very low at 0.3%.
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Neoatherosclerosis and Late Stent Thrombosis After Coronary Bare-Metal
Stent Implantation: an Optical Coherence Tomography Study
Yuetsu Kikuta, Hideo Takebayashi, Shigeki Hiramatsu, Kenji Goto, Masahito
Taniguchi, Sunao Kodama, Katsumasa Sato, Yasukazu Fujiwara, Arata Hagikura,
Seiichi Haruta
Fukuyama Cardiovascular Hospital, Fukuyama, Japan
Background: Little is available on the neointimal characteristics of the lesions with
late stent thrombosis (ST) after bare-metal stenting.
Methods: We evaluated 53 consecutive nonostial stent failure lesions in 53 patients
(8 ST and 45 restenoses) by optical coherence tomography.
Results: At the index procedure, 29 patients (55%) were treated for acute coronary
syndromes. The median duration of implant was 58.8 months (interquartile range, 8.8
to 117.7 months). Three ST patients (6%) presented with ST-segment elevation
myocardial infarction (STEMI), 1 (2%) with non-STEMI, and 4 (8%) with unstable
angina. Stent malapposition was detected in 12 lesions (23%). The risk of ST (n = 8)
versus restenosis (n = 45) was increased for the patients with low LVEF (mean ± SEM,
47.2 ± 3.2% versus 55.6 ± 1.6%, p = 0.04), high LDL/HDL cholesterol ratio (2.7 ± 0.2
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